Group 1: Investor Relations Activities - The investor relations activity was an earnings briefing held from May 15 to May 16, 2025, via an online platform [3][4] - Attendees included various investment firms and asset management companies, indicating a broad interest in the company's performance [5] Group 2: Company Developments - The completion of a new intelligent production and R&D base marks a significant upgrade in production capacity and innovation, supporting the company's growth in the biopharmaceutical sector [7] - The new facility has been recognized as a "2024 Beijing Intelligent Factory and Digital Workshop," enhancing the company's production efficiency and product quality [7] Group 3: Financial Performance - In 2024, the company reported a revenue of CNY 257 million, reflecting a year-on-year growth of 4.83% [12] - The company experienced a significant increase in tax expenses, amounting to CNY 4.0471 million, a 200.14% rise due to the new facility's operational status [11] - Financial expenses surged by CNY 8.0055 million, marking a 1,297.12% increase, primarily due to the capitalization of interest expenses related to the new facility [13] Group 4: R&D and Product Development - The company is expanding its R&D projects, focusing on recombinant protein products and aiming to enter the consumer healthcare market [9] - The antiviral oral spray product, "Lishuxing®," has received market approval, enhancing the company's competitive edge in the disinfection and prevention sector [10] - The company is advancing its clinical research on a new interferon product for chronic hepatitis B, with a focus on achieving functional cure [12] Group 5: Market Expansion and Strategy - The company successfully secured a spot in the "National Specialized and Innovative 'Little Giant' Enterprises" list, boosting its brand credibility and market reach [11] - The company has expanded its medical terminal access to over 6,000 hospitals, with an additional 1,100 new medical terminals added in 2024 [12][15] - The company is leveraging its procurement advantages to enhance market penetration, despite facing pricing pressures [12] Group 6: Intellectual Property and Innovation - The company has made strides in intellectual property management, being recognized as a "Patent Industrialization Model Enterprise" [14] - Collaborations with authoritative institutions have been established to enhance the company's patent capabilities and brand influence [14] Group 7: Clinical Applications and Future Prospects - The company is developing a new drug for treating respiratory syncytial virus (RSV) in children, addressing a significant market need [17] - The ongoing clinical trials for γδT cell therapy in cancer treatment show promising results, with several patients achieving partial remission [19][20]

公开发行股票 之保荐工作总结报告书 申万宏源证券承销保荐有限责任公司 关于北京三元基因药业股份有限公司向不特定合格投资者 申万宏源证券承销保荐有限责任公司(以下简称"申万宏源承销保荐"、"保 荐机构")作为北京三元基因药业股份有限公司(以下简称"三元基因"、"公 司")向不特定合格投资者公开发行股票的保荐机构,持续督导期间为 2021 年 1月8日至 2024年12月31日。 三元基因于 2025年4月25日披露了《2024年年度报告》,根据《证券发行 上市保荐业务管理办法》《北京证券交易所股票上市规则(试行)》《北京证券 交易所证券发行上市保荐业务管理细则》等相关法律法规文件要求,申万宏源承 销保荐现出具保荐工作总结报告书,具体内容如下: 3、本保荐机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管 理办法》及北京证券交易所(以下简称"北交所")按照《北京证券交易所证券发 行上市保荐业务管理细则》等有关规定采取的监管措施。 | 保荐机构名称 | 申万宏源证券承销保荐有限责任公司 | | --- | --- | | 注册地址 | 新疆乌鲁木齐市高新区（新市区）北京南路 358 号大成 国际大厦 20 楼 ...

证券代码：837344 证券简称：三元基因 公告编号：2025-043 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 北京三元基因药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日在北京证券交易所官网（www.bse.cn）披露了《北京三 元基因药业股份有限公司 2024 年年度报告》（公告编号：2025-014）， 为方便广大投资者更深入了解公司 2024 年年度经营业绩的具体情 况，公司拟召开 2024 年年度报告业绩说明会。 二、 说明会召开的时间、地点 公司董事长、总经理：程永庆先生 （一）会议召开时间：2025 年 5 月 15 日（星期四）15:00-17:00。 （二）会议召开地点 本次年度报告业绩说明会将采用网络远程的方式举行，投资者可 登陆中证路演中心（https://www.cs.com.cn/roadshow/）参与本次年度 业绩说明会。 三、 参加人员 北京三元基因药业股份有限公司 2024 年年度报告业绩说明会预告公告 公司副总经理：刘金 ...

证券代码：837344 证券简称：三元基因 公告编号：2025-042 北京三元基因药业股份有限公司 第四届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 1.会议召开时间：2025 年 4 月 28 日 2.会议召开地点：公司会议室 3.会议召开方式：现场方式 4.发出监事会会议通知的时间和方式：2025 年 4 月 17 日以通讯方式 发出。 5.会议主持人：许大海监事会主席。 6.召开情况合法、合规、合章程性说明： 会议的召开符合《公司法》和《公司章程》的有关规定。 二、议案审议情况 （一）审议通过《2025 年第一季度报告》 1.议案内容： 根据北京证券交易所发布的《北京证券交易所上市公司持续监管 指引第 2 号——季度报告》《关于做好上市公司 2025 年一季度报告披 露相关工作的通知》和《北京证券交易所股票上市规则》的要求，公 司监事会对公司《202 ...

2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯方式 4.发出董事会会议通知的时间和方式：2025 年 4 月 17 日以通讯 方式发出。 证券代码：837344 证券简称：三元基因 公告编号：2025-041 北京三元基因药业股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 28 日 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事程十庆因工作原因以通讯方式参与表决。 董事钱爱民因工作原因以通讯方式参与表决。 董事胡左浩因工作原因以通讯方式参与表决。 5.会议主持人：会议由程永庆董事长主持。 6.会议列席人员：监事会成员、董事会秘书以及公司其他高级管 理人员列席了会议。 7.召开情况合法、合规、合章程性说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 （二）会议出席情况 二、议案审议情况 （一）审议通过《2025 年第一季度报告》 1.议案内容： ...

Financial Performance - Net profit attributable to shareholders for Q1 2025 was CNY -12,250,556.92, representing a decline of 735.27% year-over-year [12]. - Operating revenue for Q1 2025 was CNY 45,021,673.04, down 6.11% from the same period in 2024 [12]. - The company's basic earnings per share for Q1 2025 was CNY -0.10, a decrease of 600.00% year-over-year [12]. - Total revenue for Q1 2025 was CNY 45,021,673.04, a decrease of 6.06% compared to CNY 47,952,373.12 in Q1 2024 [51]. - Net profit for Q1 2025 was a loss of CNY 12,250,556.92, compared to a profit of CNY 1,928,398.18 in Q1 2024 [52]. - The company reported a total comprehensive loss of ¥11,980,741.88 for Q1 2025, compared to a comprehensive income of ¥2,427,166.30 in Q1 2024 [56]. Assets and Liabilities - Total assets as of March 31, 2025, were CNY 1,199,269,643.07, a decrease of 2.44% compared to the end of 2024 [12]. - The total liabilities as of March 31, 2025, were CNY 590,699,872.29, down from CNY 608,480,109.76 at the end of 2024 [47]. - The company’s total liabilities to assets ratio was 49.25% as of March 31, 2025, slightly down from 49.50% at the end of 2024 [12]. - The total value of assets under mortgage is 554,848,109.29, which accounts for 46.26% of the total assets [28]. - The company's non-current assets totaled CNY 996,029,678.91 as of March 31, 2025, slightly up from CNY 989,433,003.73 at the end of 2024 [46]. Cash Flow - The net cash flow from operating activities was CNY 699,774.62, a significant decrease of 95.41% compared to the previous year [14]. - Operating cash flow for Q1 2025 was ¥699,774.62, a decrease of 95.42% from ¥15,256,581.97 in Q1 2024 [57]. - The ending cash and cash equivalents balance decreased to $83,274,038.58 from $153,656,838.74, reflecting a decline of about 45.8% [59]. - The net increase in cash and cash equivalents was -$25,839,694.76, worsening from -$20,401,204.55 [59]. Research and Development - Research and development expenses increased by 199.95% to CNY 8,773,200.96, driven by clinical trials for new products [14]. - The company plans to continue investing in R&D for new therapies, indicating a focus on market expansion and innovation [14]. - The company has ongoing new drug research and development projects, increasing investment in R&D to support long-term growth [30]. - The company incurred R&D expenses of ¥8,773,200.96 in Q1 2025, significantly higher than ¥2,924,856.44 in Q1 2024, reflecting increased investment in innovation [53]. Shareholder Information - The total number of unrestricted shares is 113,560,796, accounting for 93.23% of the total share capital [18]. - The total share capital is 121,810,000 shares, with 6,422 common shareholders [18]. - The largest shareholder, Beijing Southeast Pharmaceutical Investment Holdings Co., Ltd., holds 46,907,925 shares, representing 38.51% of the total shares [20]. Operational Developments - The company has completed Phase III clinical trials for human interferon α1b nebulization treatment for pediatric RSV pneumonia, demonstrating significant improvement in key clinical symptoms such as respiratory distress [31]. - The new PEG-integrated interferon mutant injection combined with genetic testing aims to significantly increase the clinical cure rate for chronic hepatitis B, with 791 subjects enrolled in the clinical study [32][33]. - The company has successfully launched the antiviral oral spray (brand name: Lishuxing®), enhancing its market competitiveness in disinfection products and expanding its product line [36]. - The company is advancing the γδT cell tumor immunotherapy project, focusing on developing cost-effective "off-the-shelf" cell therapy products for various cancers, including acute and refractory leukemia [39]. Strategic Initiatives - The company is constructing a smart production and R&D base aimed at achieving "Industry 4.0" standards in biopharmaceuticals, which will support new product launches and contract development manufacturing (CDMO) services [40]. - The company has enhanced its digital operations, improving the efficiency of various information systems, including SCADA, DCS, MES, and others, leading to better overall equipment effectiveness (OEE) and compliance in production [41]. - A new generation of equipment management information system has been successfully launched, establishing a comprehensive lifecycle management system for production line equipment, which significantly improves management efficiency and production capacity [42].

Core Viewpoint - San Yuan Gene reported a revenue of approximately 257 million yuan for 2024, marking a year-on-year growth of 4.83%, alongside a significant increase in net cash flow from operating activities by 63.23% [2] Group 1: Financial Performance - The company achieved a revenue of approximately 257 million yuan in 2024, reflecting a year-on-year growth of 4.83% [2] - The net cash flow from operating activities increased by 63.23% compared to the previous year [2] Group 2: Research and Development - R&D expenses increased by 8.49 million yuan, a growth of 64.90%, primarily due to advancements in clinical trials for new PEG-integrated interferon mutant injection and γδT cell tumor immunotherapy [2] - The company has established five major technology platforms to support continuous innovation, including platforms for recombinant protein drug expression, high stability solutions, long-acting interferon preparation, inhalation formulations, and universal immune cell therapy [3] Group 3: Clinical Research and Development - The company is actively advancing the development of γδT cell tumor immunotherapy, aiming to create cost-effective "off-the-shelf" cell therapy products for broader clinical applications [4] - Clinical studies have been initiated for γδT cell therapy in various cancers, including melanoma and acute myeloid leukemia, with positive safety results reported [5] - A collaboration with Beijing Jiade and a leading γδT cell therapy team has been established to develop an international tumor immunotherapy platform [5][6] Group 4: Market Expansion - An expert consensus on the use of human interferon α1b for melanoma treatment was published, providing a solid foundation for expanding the company's market in tumor treatment [7]

一、主要会计数据和财务指标 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 8126.88万股，累计占流通股比： 71.56%，较上期变化： -60.71 万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 北京东南医药投资控股有限公司 | 4690.79 | 41.31 | 不变 | | 浙江圣达科技发展有限公司 | 1457.03 | 12.83 | 不变 | | 张红斌 | 927.67 | 8.17 | 不变 | | 北京元进医药投资管理中心(普通合伙) | 274.00 | 2.41 | 不变 | | 鲍劲松 | 197.85 | 1.74 | -41.53 | | 程永庆 | 156.96 | 1.38 | 不变 | | 金桂英 | 133.89 | 1.18 | -26.11 | | 沙天韵 | 128.82 | 1.13 | 新进 | | 胡光渭 | 113.42 | 1.00 | -6.89 | | 晏征宇 | 46.45 | 0.41 | 不变 | ...

证券代码：837344 证券简称：三元基因 公告编号：2025-012 北京三元基因药业股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 3 月 20 日 2.会议召开地点：公司会议室 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事钱爱民因工作原因缺席，委托董事邵荣光代为表决。 董事程十庆、胡左浩因工作原因以通讯方式参与表决。 二、议案审议情况 3.会议召开方式：会议以现场+通讯方式召开 4.发出董事会会议通知的时间和方式：2025 年 3 月 9 日以通讯方 式发出 5.会议主持人：会议由程永庆董事长主持。 6.会议列席人员：监事会成员、董事会秘书以及公司其他高级管 理人员列席了会议。 7.召开情况合法、合规、合章程性说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 （二）会议出席情况 （一）审议通过《关于补选公司第四届董事会审计委员会委员的议案》 1.议案内容 ...

证券代码：837344 证券简称：三元基因 公告编号：2025‐013 北京三元基因药业股份有限公司 公司于 2025 年 3 月 20 日召开第四届董事会第三次会议，审议通 过了《关于补选公司第四届董事会审计委员会委员的议案》，补选后 的审计委员会委员任期自本次董事会审议通过之日起至第四届董事 会届满之日止，如在任期内不再担任公司董事职务，自动失去委员资 格。根据董事会提名，补选前后的公司第四届董事会审计委员会成员 组成情况如下： 补选后： | 董事会专门委员会 | 委员 | 主任委员（召集人） | | --- | --- | --- | | 审计委员会 | 钱爱民、邵荣光、杨大军 | 钱爱民 | 三、上述人员补选对公司的影响 本次董事会审计委员会委员补选符合《公司法》、《北京证券交易 所股票上市规则（试行）》、《公司章程》及《董事会审计委员会工作 细则》等相关规定，符合公司治理要求，对公司生产经营活动具有积 极影响。 四、备查文件 （一）与会董事签字确认并加盖董事会印章的公司《第四届董事 会第三次会议决议》。 关于补选第四届董事会审计委员会委员的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整， ...